Microdosing psilocybin for depression: What the research actually shows

Psilocybin therapy has generated enormous scientific and public interest as a potential treatment for depression, PTSD, and addiction. But much of the public conversation conflates two very different approaches: therapeutic (full-dose) psilocybin-assisted therapy and microdosing. The evidence for each is different, and understanding the distinction matters.

Therapeutic psilocybin: Strong evidence

Full-dose psilocybin (25mg, producing a significant psychedelic experience) administered in a structured therapeutic setting has shown remarkable results in clinical trials. FDA-designated it a "Breakthrough Therapy" for treatment-resistant depression. Studies at Johns Hopkins and NYU have shown response rates of 50-70% in patients who had not responded to conventional antidepressants. These sessions involve extensive preparation, a 6-8 hour guided session with trained therapists, and integration therapy afterward. This is a clinical intervention, not recreational use.

Microdosing: Weaker evidence

Microdosing involves taking sub-perceptual doses (1/10th to 1/20th of a full dose) every few days. Despite enormous popularity and enthusiastic anecdotal reports, the rigorous scientific evidence for microdosing is much weaker than for therapeutic dosing. The largest placebo-controlled study to date (2021, Nature) found no significant difference between psilocybin microdoses and placebo for depression, anxiety, or cognitive performance. The observed benefits may be largely attributable to expectation effects (placebo), which are powerful in psychedelic research.

Legal status

Psilocybin remains a Schedule I substance federally. Oregon and Colorado have legalized therapeutic psilocybin programs with licensed facilitators. Several cities have decriminalized possession. Therapeutic psilocybin sessions in Oregon cost approximately $1,500-$3,500 and are not covered by insurance. Obtaining psilocybin outside these frameworks is illegal and unregulated, with no guarantees of purity, dosage, or safety.

The responsible takeaway

If you have treatment-resistant depression, therapeutic psilocybin in a legal, supervised setting is a legitimate option worth discussing with your psychiatrist. If you are considering microdosing, understand that the evidence does not yet support the claims, and that self-medicating with an illegal, unregulated substance carries legal and health risks. Evidence-based treatments for depression (therapy, SSRIs, SNRIs, ketamine, TMS) should not be abandoned in favor of approaches with weaker evidence.

Mental health facilities

Authoritative sources

This article references guidelines from: NIH · NAMI · APA · Harvard Health · Mayo Clinic

Frequently asked questions

Disclaimer: Informational only. Not medical advice. SAMHSA: 1-800-662-4357.